Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis
- 1 January 2001
- journal article
- research article
- Published by Taylor & Francis in Free Radical Research
- Vol. 34 (1) , 33-44
- https://doi.org/10.1080/10715760100300041
Abstract
Oxidative stress may be an important factor in the development of diabetic complications. Advanced glycation end-products have drown attention as potential sources of oxidative stress in diabetes. We investigated the protective effects of fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on oxidative DNA damage from reactive oxygen species or advanced glycation end-products in vitro, as well as effects of main fluvastatin metabolites and other inhibitors of the same enzyme, pravastatin and simvastatin. Protective effects were assessed in terms of the DNA breakage rate in a single-stranded phage DNA system in vitro. DNA was exposed to either reactive oxygen species or advanced glycation end-products. Fluvastatin and its metabolites showed a strong protective effect comparable to those seen with thiourea and mannitol, though pravastatin and simvastatin did not exert clear protective effects. Furthermore, fluvastatin reduced the mutagenesis by reactive oxygen species or advanced glycation end-products in Salmonella typhimurium test strains. Both pravastatin and simvastatin still lacked protective activity. Fluvastatin and its metabolites protect against oxidative DNA damage and may reduce risk of consequent diabetic complications.Keywords
This publication has 26 references indexed in Scilit:
- Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitroBiochemical Pharmacology, 1999
- Superoxide Anion Scavenging Properties of Fluvastatin and Its Metabolites.CHEMICAL & PHARMACEUTICAL BULLETIN, 1999
- An in Vitro Study of the Hydroxyl Radical Scavenging Property of Fluvastatin, an HMG-CoA Reductase Inhibitor.CHEMICAL & PHARMACEUTICAL BULLETIN, 1999
- Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metalsEuropean Journal of Clinical Pharmacology, 1997
- Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDLAtherosclerosis, 1997
- The effects of vitamin C supplementation on biomarkers of oxygen radical generated damage in human volunteers with “low” or “high” cholesterol levelsEnvironmental and Molecular Mutagenesis, 1997
- Reducing sugars trigger oxidative modification and apoptosis in pancreatic β-cells by provoking oxidative stress through the glycation reactionBiochemical Journal, 1996
- Inhibitory effects of fluvastatin, a new HMG‐CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol‐fed rabbitsBritish Journal of Pharmacology, 1996
- FluvastatinDrugs, 1996
- Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol depositionProceedings of the National Academy of Sciences, 1979